48 results about "Ifn alpha" patented technology

The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.

Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-α antibodies as well as IFN-α binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

The invention relates to bio-pharmaceutical engineer technology domain. At present, the therapeutic drugs for HBV infection mainly depend on IFN-Alpha and nucleotide analog, which can not kill virus thoroughly with worse remote therapeutic effect. The invention provides a cytotoxic T cell epitope vaccine for hepatitis B, comprising a fused polypeptide formed by connecting 21 CTL epitopes selectedfrom CTL epitopes data of HBV antigen and two universal epitopes of auxiliary T lymphocyte. Saccharomyces Serevisiae is selected to express the fused antigen and mixes with immunologic adjvant. The said vaccine can activate and enhance the cellular immune response of patient with chronic HBV infection. The vaccine can also promote the immune elimination of HBV, and can be used for treatment of chronic hepatitis B.

The invention discloses a method for preparing porcine recombinant IFN-alpha. The method is to use a special primer - PCR to amplify target genes of the porcine IFN-alpha, to connect the target genes with an expression vector - pET-28a and an expression vector - pGEX-5X, to transform colon bacillus, to make the colon bacillus highly efficiently express the porcine IFN-alpha and to prepare porcinerecombinant IFN-alpha freeze-dried injection through the techniques such as high purification, sterilization, split charging, freeze-drying and so on. The method is shown to have obvious treatment effect on porcine virus diarrhea, influenza and so on and be superior to similar products in the aspects of safety and cure rate through safety experiment, IFN efficacy inspection and clinic probation. The preparation technique is simple; industrialized production is easy; transportation and preservation are easy after freeze-drying. After the porcine recombinant IFN-alpha is injected into a porcinebody, the porcine recombinant IFN-alpha is characterized by good healing effect, reliable assembly, no side effect like inocuity and so on, can be used for curing diseases like the porcine virus diarrhea, the influenza and so on, and is novel high-efficient safe nonpersistent broad-spectrum antiviral preparation.

The invention discloses a recombinant interferon--BCG Vaccine bacterial strain and its preparing method, transferring the composed pshuttle phIFN-alpha-2B into the BCG to compose Rbcg-hIFN-alpha-2B bacterial strain. Because it can secrete the interferon IFN-alpha-2B, it can reduce the usage of BCG as compared with that of the wild BCG on the condition of reaching the same and even increased immune effect, thus reducing toxic and side effect; and it can secrete cell factors at the properest time and part. Therefore, it lays the foundation of application to curing cystic tumors.